Hi, I posted a note about the January article in Bloomberg about Teva dropping its alliance with CureTech over the disappointing results of CureTech’s “anti-PD1” drug, CT-011. I know of no one who received a positive response with the drug (and there are approximately 80 of us who were in this phase 1 trial).
The worst aspect of this is that we are now excluded from participation in either the Merck or BMS anti-PD1 trials, since we have already technically been on an anti-PD1 drug. My argument is that since it’s not been at all effective, it shouldn’t “count” as an exclusion from the other trials – what are we supposed to do, after participating in this trial in good faith?
CureTech should be obliged to make public its phase 1 results. If it is as totally ineffective as I believe it is, having it made public might make a difference in the other drug companies’ exclusion positions.
If you have any opinions on this, or were a participant in the trial, please respond.
Best,
Jonathan